Angiotensin II (Ang II) activates the RhoA/Rho kinase signaling pathway, inhibits myosin light chain phosphatase (MLCP) and endothelial nitric oxide synthase (eNOS) activity, leading to vasoconstriction and endothelial dysfunction (19). This evidence concerns the gene NOS3 and endothelial dysfunction.